Iosat Tablet
NDC Package 51803-002-01
Package Information
Iosat (potassium iodide) tablets is use as directed by public officials in the event of a nuclear radiation emergencydo not take more than 1 dose in 24 hourstablets can be whole or crushed and mixed in milk, baby formula, water, orange juice, flat soda like cola, or raspberry syrupThe liquid mixture should be given to infants, young children, and others who cannot swallow tablets; see consumer package insert on how to make a liquid mixture.AgeDoseAdults over 18 years2 tablets (whole or crushed) daily (130 mg)Children over 12 years to 18 years who weigh at least 150 pounds2 tablets (whole or crushed) daily (130 mg)Children over 12 years to 18 years who weigh less than 150 pounds1 tablet (whole or crushed) daily (65 mg)Children over 3 years to 12 years1 tablet (whole or crushed) daily (65 mg)Children over 1 month to 3 years1/2 tablet (crushed) 32.5 mg daily as directed in the consumer package insertBirth to 1 month16.25 mg daily as directed in the consumer package insertIf pregnant, breastfeeding, have a baby up to 1 month of age or have thyroid disease (except nodular thyroid disease with heart disease), take as directed above and contact a doctor as soon as possible. This formulation utilizes a tablet delivery system. Marketed by Anbex Inc., this product is identified by NDC 51803-002 and is authorized under FDA application NDA018664.
Identification & Billing
- RxCUI: 1423814 - Iosat 65 MG Oral Tablet
- RxCUI: 1423814 - potassium iodide 65 MG Oral Tablet [Iosat]
- RxCUI: 1423814 - K+ Iodide 65 MG Oral Tablet [Iosat]
- RxCUI: 1423814 - Pot Iodide 65 MG Oral Tablet [Iosat]
- RxCUI: 430174 - potassium iodide 65 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 51803 - Anbex Inc.
- 51803-002 - Iosat
- 51803-002-01 - 20 TABLET in 1 PACKAGE
- 51803-002 - Iosat
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (51803-002). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 51803-002-01 identifies a specific commercial package of 20 tablet in 1 package of Iosat, a human over the counter drug labeled by Anbex Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 20 billable units per package. This tablet is formulated for oral use and contains potassium iodide as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Anbex Inc. on May 01, 2013. The current certification is valid through December 31, 2026.
How is this Anbex Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 51803000201. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 20 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.